1. Home
  2. GOTU vs CBIO Comparison

GOTU vs CBIO Comparison

Compare GOTU & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GOTU

Gaotu Techedu Inc.

HOLD

Current Price

$1.94

Market Cap

469.8M

Sector

Real Estate

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$18.14

Market Cap

557.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOTU
CBIO
Founded
2014
2003
Country
China
United States
Employees
N/A
44
Industry
Other Consumer Services
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
469.8M
557.8M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
GOTU
CBIO
Price
$1.94
$18.14
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$26.67
AVG Volume (30 Days)
319.0K
297.1K
Earning Date
05-15-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.33
N/A
Revenue Next Year
$13.02
$279.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.84
$8.72
52 Week High
$4.12
$27.41

Technical Indicators

Market Signals
Indicator
GOTU
CBIO
Relative Strength Index (RSI) 47.86 44.96
Support Level $1.86 $10.83
Resistance Level $2.04 $20.58
Average True Range (ATR) 0.05 2.53
MACD 0.01 -0.85
Stochastic Oscillator 51.72 24.32

Price Performance

Historical Comparison
GOTU
CBIO

About GOTU Gaotu Techedu Inc.

Gaotu Techedu Inc is a technology-driven education company that provides online live courses in a large-class setting backed by its proprietary technology infrastructure. The company offers courses in large-class format, which amplifies the benefits of online education and allows it to rapidly expand its student base. It operates solely in the PRC and all assets are located in the PRC. The learning services that the company offers include Traditional Learning Services, Non-Academic Tutoring Services, and College Student and Adult Education Services. It derives maximum revenue from Learning Services and also from Educational content & digitalized learning products.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: